![]()
|
|
||||||||
J. Biol. Chem., Vol. 283, Issue 18, 12175-12187, May 2, 2008
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||








1
From the
Department of Physiology, The University of Tennessee Health Science Center, Memphis, Tennessee 38163, the
Department of Chemistry and Computational Research on Materials Institute, University of Memphis, Memphis, Tennessee 38152, and the ¶Department of Pathology, Ohio State University, Columbus, Ohio 43210
Lysophosphatidic acid (LPA) is a ligand for three endothelial differentiation gene family G protein-coupled receptors, LPA1–3. We performed computational modeling-guided mutagenesis of conserved residues in transmembrane domains 3, 4, 5, and 7 of LPA1–3 predicted to interact with the glycerophosphate motif of LPA C18:1. The mutants were expressed in RH7777 cells, and the efficacy (Emax) and potency (EC50) of LPA-elicited Ca2+ transients were measured. Mutation to alanine of R3.28 universally decreased both the efficacy and potency in LPA1–3 and eliminated strong ionic interactions in the modeled LPA complexes. The alanine mutation at Q3.29 decreased modeled interactions and activation in LPA1 and LPA2 more than in LPA3. The mutation W4.64A had no effect on activation and modeled LPA interaction of LPA1 and LPA2 but reduced the activation and modeled interactions of LPA3. The R5.38A mutant of LPA2 and R5.38N mutant of LPA3 showed diminished activation by LPA; however, in LPA1 the D5.38A mutation did not, and mutation to arginine enhanced receptor activation. In LPA2, K7.36A decreased the potency of LPA; in LPA1 this same mutation increased the Emax. In LPA3, R7.36A had almost no effect on receptor activation; however, the mutation K7.35A increased the EC50 in response to LPA 10-fold. In LPA1–3, the mutation Q3.29E caused a modest increase in EC50 in response to LPA but caused the LPA receptors to become more responsive to sphingosine 1-phosphate (S1P). Surprisingly micromolar concentrations of S1P activated the wild type LPA2 and LPA3 receptors, indicating that S1P may function as a weak agonist of endothelial differentiation gene family LPA receptors.
Received for publication, October 26, 2007 , and in revised form, February 15, 2008.
* This work was supported by United States Public Health Service Grants HL61469 (to G. T.), CA921160 (to G. T.), HL084007 (to A. L. P.), and HL07641-19 (to W. J. V.) and by Southeast American Heart Association Postdoctoral Fellowship 0625325 (to Y. F.) and predoctoral fellowship (to J. I. F.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1 and 2.
1 To whom correspondence should be addressed: Dept. of Physiology, The University of Tennessee Health Science Center Memphis, 894 Union Ave., Memphis, TN 38163. Tel.: 901-448-4793; E-mail: gtigyi{at}physio1.utmem.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |